• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will U.S. Manufacturing Deal Change Becton Dickinson (BDX) Stock Narrative

    Simply Wall St·10/15/2026 12:37:25
    語音播報
    • BD announced a multi year partnership with the U.S. Government to expand domestic production of essential medical consumables and reported positive nine month AGILITY trial results for the Revello Vascular Covered Stent in iliac artery disease.
    • The combination of large scale U.S. manufacturing investment and encouraging Revello stent data highlights how Becton Dickinson is tying capital spending directly to product depth in critical care categories where reliability and clinical evidence matter to hospital buyers.
    • This article examines how Becton Dickinson's investment narrative is affected by the large U.S. manufacturing build out announced with the government.

    Scan other hospital supply and medtech players tying capacity builds to clinical evidence by reviewing our curated list of list of solid balance sheet and fundamentals (25 results).

    Becton Dickinson Investment Narrative Recap

    To own Becton Dickinson, you need to believe the medtech portfolio can keep compounding through recurring consumables, higher margin platforms and steady execution of the BD Excellence program, even while headline revenue growth is modest. The short term swing factor remains how cleanly management handles product quality, regulatory oversight and the Alaris replacement headwind that is already flagged for 2026 and 2027.

    The latest U.S. manufacturing expansion and Revello trial update mostly reinforce the existing thesis rather than change it. The bigger near term risk still sits in further recalls, regulatory actions or quality issues that could slow that margin story, especially given debt is not well covered by operating cash flow.

    The AGILITY data on the Revello Vascular Covered Stent sits closest to the core Becton Dickinson narrative because it speaks directly to product depth in higher value interventional procedures. Strong nine month safety and patency outcomes, plus meaningful functional gains, help support that the Interventional segment can remain one of the more attractive parts of the portfolio.

    For catalysts, Revello sits alongside advanced tissue regeneration, connected care platforms and biologic delivery work, including the roughly 100 GLP 1 related agreements already in place. The key execution test is whether BD can keep converting this kind of clinical evidence into durable procedure volume and recurring hardware plus consumables revenue without triggering fresh regulatory or quality setbacks.

    Becton Dickinson's current analyst storyline points to revenues of $21.4 billion and earnings of $3.3 billion by 2029, compared with earnings today of $1.6 billion. This path assumes revenue declines of 1.6% per year and implies earnings would roughly double, a rise of about $1.7 billion, if that consensus forecast plays out.

    Uncover why Becton Dickinson's fair value indicates a 4% potential upside to its current price that could narrow quickly if sentiment shifts.

    NYSE:BDX 1-Year Stock Price Chart
    NYSE:BDX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view treats the Revello stent as a side story and focuses on margin pressure. The most bearish analysts were penciling in revenue of about $21.1b and earnings of roughly $2.4b by 2029 for Becton Dickinson before this news. That perspective is more cautious and shows how far opinions can spread, so it pays to explore several narratives that might now shift.

    Explore 2 other Becton Dickinson fair value estimates, including one that suggests it could be worth just $195.67.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more Becton Dickinson style investment ideas?

    If the Becton Dickinson story has you thinking about portfolio gaps, it can help to compare it with other companies that have clear balance sheets, income streams and capital discipline using the Simply Wall St Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.